Evidence map›Paper›PMID 30933987›Full record

ArticlePloS one2019

Design of stable magnetic hybrid nanoparticles of Si-entrapped HRP.

Sonali Correa, Sara Puertas, Lucía Gutiérrez, Laura Asín, Jesús Martínez de la Fuente, Valeria Grazú, Lorena Betancor

Abstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Reflections on the 2nd International Congress on NanoBioEngineering 2020.Frontiers in bioengineering and biotechnology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sonali CorreaLaboratorio de Biotecnología, Universidad ORT Uruguay, Montevideo, Uruguay.
Sara PuertasNanoimmunotech S.L., Zaragoza, Spain.
Lucía GutiérrezInstituto de Nanociencia de Aragón, Universidad de Zaragoza, Campus Río Ebro, Edificio I+D, Zaragoza, Spain.
Laura AsínCentro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.
Jesús Martínez de la FuenteInstituto de Ciencia de Materiales de Aragón (ICMA), Consejo Superior de Investigaciones Científica, Zaragoza, Spain.
Valeria GrazúInstituto de Ciencia de Materiales de Aragón (ICMA), Consejo Superior de Investigaciones Científica, Zaragoza, Spain.
Lorena BetancorLaboratorio de Biotecnología, Universidad ORT Uruguay, Montevideo, Uruguay.ORCID 0000-0002-0569-0499

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hybrid and composite nanoparticles represent an attractive material for enzyme integration due to possible synergic advantages of the structural builders in the properties of the nanobiocatalyst. In this study, we report the synthesis of a new stable hybrid nanobiocatalyst formed by biomimetic silica (Si) nanoparticles entrapping both Horseradish Peroxidase (HRP) (EC 1.11.1.7) and magnetic nanoparticles (MNPs). We have demonstrated that tailoring of the synthetic reagents and post immobilization treatments greatly impacted physical and biocatalytic properties such as an unprecedented ~280 times increase in the half-life time in thermal stability experiments. The optimized nanohybrid biocatalyst that showed superparamagnetic behaviour, was effective in the batch conversion of indole-3-acetic acid, a prodrug used in Direct Enzyme Prodrug Therapy (DEPT). Our system, that was not cytotoxic per se, showed enhanced cytotoxic activity in the presence of the prodrug towards HCT-116, a colorectal cancer cell line. The strategy developed proved to be effective in obtaining a stabilized nanobiocatalyst combining three different organic/inorganic materials with potential in DEPT and other biotechnological applications.

Indexed as

Antineoplastic AgentsBiocatalysisDrug Delivery SystemsDrug Evaluation, PreclinicalEnzymes, ImmobilizedHalf-LifeHCT116 CellsHorseradish PeroxidaseHumansIndoleacetic AcidsMagnetite NanoparticlesNanocompositesProdrugsSilicon DioxideAntineoplastic AgentsEnzymes, ImmobilizedHorseradish Peroxidaseindoleacetic acidIndoleacetic AcidsMagnetite NanoparticlesProdrugsSilicon Dioxide

Identifiers

PMID30933987
PMCPMC6443235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.